{
    "nct_id": "NCT03400826",
    "official_title": "A Double-blinded, Phase II, Randomized Control Trial to Study the Effects of Simvastatin in Patients With Uterine Leiomyoma",
    "inclusion_criteria": "* Signed informed written consent.\n* Gender: female.\n* Age: 18-55 years at time of signing consent.\n* BMI of subjects: < 45 kg/m2.\n* Uterine fibroids:\n* Diagnosed by ultrasound (MRI will be used only if ultrasound is inconclusive).\n* Number: any number of fibroids.\n* Location: submucosal or intramural.\n* At least one fibroid of diameter > 3cm.\n* Symptoms: one or more of the following symptoms of heavy menstrual bleeding (HMB), defined as: Experienced cyclic (22 to 35 days) abnormal uterine bleeding (heavy or prolonged) in at least 3 of the last 6 menstrual periods, including menstrual bleeding lasting 5 or more days or heavy bleeding per participant recall. Examples of heavy bleeding may include, but are not limited to the following:\n* Requires the use of double protection to manage menstrual bleeding.\n* Menstrual bleeding accompanied by the sensation of \"gushing\" or \"flooding\".\n* Saturates more than 1 tampon or sanitary pad per hour for 3 or more consecutive hours.\n* Regularly needs to change the tampon or sanitary pad at night or regularly soils bedclothes.\n* Heavy bleeding that affects work, school, or social activities.\n* Pelvic pain/ pressure likely caused by fibroids.\n* Plan for surgery (hysterectomy or myomectomy).\n* Normal Pap smear within the last year.\n* Use of contraception during study such as non-hormonal oral contraceptives, intrauterine devices (IUD)/ intrauterine systems (IUS), barrier contraceptives, abstinence or sterilization.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 55 Years",
    "exclusion_criteria": "* Pregnancy or lactation.\n* Previous or current uterine, cervical or ovarian cancer.\n* Current endometrial hyperplasia or history of atypical endometrial hyperplasia. Endometrial biopsy will be done during screening (if not done within last 12 months).\n* Suspicion of leiomyosarcoma.\n* Recent rapid growth of fibroids (i.e. doubling in size within 1-6 months period).\n* Unevaluated gynecologic abnormalities (unexplained vaginal bleeding, cervical dysplasia, or abnormal adnexal/ovarian mass).\n* Menopausal status.\n* Surgery is urgently indicated (< 3 months) for medical or social reasons.\n* Hemoglobin â‰¤ 6 g/dL.\n* Currently enrolled in another investigational study.\n* Mental condition or other barrier preventing informed written consent.\n* Allergy or hypersensitivity to simvastatin.\n* Current use of simvastatin or other drugs of the same class.\n* Concomitant administration of strong CYP3A4 inhibitors including itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, and cobicistat-containing products.\n* Concomitant administration of gemfibrozil, cyclosporine, or danazol, verapamil, diltiazem, amiodarone, diltiazem, dronedarone, amlodipine, ranolazine, lomitapide, and grapefruit juice.\n* Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels.( elevation of aspartate transaminase and/or alanine transaminase > 2 s.d. above the normal range at screening visit)\n* Known increased risk or diagnosis of a myopathy.",
    "miscellaneous_criteria": ""
}